Marie‐Laure Risse

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations

Medicine, Pharmacology, Pharmacotherapy +12

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

Alexandre Santos, Sylvie Zanetta, Thierry Cresteil et al. · PubMed · 2000 · 213 citations

Medicine, Pharmacokinetics, Pharmacology +17

A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors

Gilles Vassal, François Doz, Didier Frappaz et al. · Journal of Clinical Oncology · 2003 · 102 citations

Medicine, Oncology, Pharmacotherapy +17

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Thomas G. Martin, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · Blood Cancer Journal · 2023 · 95 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1^st-line advanced gastric cancer patients

Magdolna Dank, J. Załuski, C. Barone et al. · Journal of Clinical Oncology · 2005 · 87 citations

Medicine, Oncology, Pharmacology +5